Rapport Therapeutics

Public

Boston, MassachusettsHealthcarehttps://www.rapportrx.com

Last Round

IPO Announced

Jun 6, 2024

Est. Valuation

$621.8M

Total Funding Raised

$424.4M

Company Overview

Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small molecule precision medicines for central nervous system (CNS), neurological, and psychiatric disorders. The company's proprietary RAP (receptor-associated proteins) technology platform allows for the specific targeting of receptors in distinct neuroanatomical regions, aiming to create treatments with better efficacy and fewer side effects than existing therapies. Its lead program, RAP-219, is in clinical trials for conditions including drug-resistant focal onset seizures and bipolar mania. Founded in 2022, the company went public in June 2024 and trades on the Nasdaq under the ticker RAPP.

Sector

Healthcare

AI Layer

Non-AI

Keywords

receptor-associated protein (RAP) targeting platformprecision small molecule medicines for CNS disordersTARPγ8 selective small moleculetreatment for drug-resistant focal onset seizuresneuroanatomically specific CNS therapeuticsoral medication for peripheral neuropathic paintherapeutics for bipolar disorderclinical-stage CNS drug developmentα6 nAChR modulators for chronic painα9α10 nAChR modulators for hearing disorders

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Rapport Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Rapport Therapeutics Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
IPO Announced	Jun 6, 2024
Series B	Aug 23, 2023
Series A	Mar 7, 2023

View all Funding Rounds

Rapport Therapeutics Investors

Notable investors and investment history

Investor	Rounds
Jefferies	IPO
Perceptive Advisors	Series B
Fidelity Management & Research Company	Series B
TD Cowen	IPO
Invus Opportunities	Series A
Logos Capital	Series B
ARCH Venture Partners	Series A, Series B, IPO

View all Investors

Rapport Therapeutics Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Rapport Therapeutics Filings

SEC and related filings with document metadata.

Firmographic Details

HeadquartersBoston, Massachusetts

Employee Range103

Year Founded2022

Last FundingJun 6, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.